Drug Discovery World

JULY 14, 2022

Pharmaceutical company SIGA Technologies has announced that its oral therapy tecovirimat has been approved in the UK for the treatment of smallpox, monkeypox, cowpox. . for the treatment of smallpox. Official comments . “We

Treatment 130

Treatment Pharmaceutical Companies Vaccine Virus 130

Drug Target Review

JANUARY 23, 2024

What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade.

Treatment 119

Treatment Immune Response Vaccine Therapies 119

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The post Merck and Moderna to jointly develop personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

Drug Discovery World

APRIL 16, 2023

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. billion, compared to $19.9 Cancer is king .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

OCTOBER 24, 2022

New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses. . Rather than messenger RNA as a vaccine, this shows that mRNA can be used as a universal therapy against different coronaviruses,” said Gaurav Sahay, OSU and the Texas Biomedical Research Institute.

Treatment 100

Treatment RNA Protein Production Packaging 100

Drug Discovery World

APRIL 19, 2024

The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s. News round-up for 15-19 April by DDW Digital Content Editor Diana Spencer.

Clinical Trials 130

Clinical Trials Vaccine Trials Drugs 130

Drug Discovery World

OCTOBER 27, 2023

My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases. News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer.

Vaccine 130

Vaccine Drugs Therapies Clinical Trials 130

Drug Target Review

JANUARY 15, 2024

Cancer is a disease driven by variable genetic mutations. Could you provide insights into the driving factors behind exploring novel treatments for cancer types? Could you provide further details on how this phenomenon could impact broader treatment outcomes? What aspects prompted this research direction?

Treatment 104

Treatment Immune Response Clinical Trials Therapies 104

FDA Law Blog: Drug Discovery

JUNE 12, 2024

Sasinowski — Hyman, Phelps & McNamara (HPM) would like to congratulate the 7 rare disease programs selected for the inaugural class of the FDA’s “Support for clinical Trials Advancing Rare disease Treatment” (START) pilot program.

Disease 59

Disease Clinical Trials FDA Clinical Development 59

Drug Discovery World

NOVEMBER 20, 2023

Engineering biology is reshaping the world, from enabling the rapid development of vaccines to providing alternatives to petroleum fuels. Biologics represents the fastest-growing sector of the pharmaceutical industry, with hundreds of therapies approved in recent years 3,4.

DNA 174

DNA Engineering Vaccine Therapies 174

Drug Discovery World

MAY 23, 2024

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The research team has already used the virus in a small Phase I trial where responses to the treatment were seen in 11 out of 12 children.

Virus 148

Virus Immune Response Vaccine Engineering 148

Drug Discovery World

AUGUST 16, 2023

The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. Therefore, it is now more critical than ever to advance the science to develop the next generation of RNA therapies, leveraging this molecule as a therapeutic modality with transformational potential.

RNA 130

RNA DNA Therapies Small Molecule 130

Drug Discovery World

NOVEMBER 4, 2022

In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Covid-19 vaccine less effective in the immunocompromised . Covid-19 vaccine less effective in the immunocompromised . The top stories: .

Vaccine 130

Vaccine Therapies Drugs Virus 130

Drug Discovery World

OCTOBER 30, 2023

The news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Clinical Trials 130

Clinical Trials Vaccine Therapies Trials 130

Vial

DECEMBER 11, 2023

Pathophysiological evidence links HCV infections to the risk of liver diseases such as hepatocellular carcinoma (HCC) and liver cirrhosis. Despite advances in clinical research, there remain significant challenges as only 20% of HCV cases are diagnosed, and of these, only 15% receive treatment.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Discovery World

JANUARY 9, 2024

They include therapeutics for conditions including breast cancer, haemophilia A, sickle cell disease, Crohn’s disease, ulcerative colitis, respiratory syncytial virus (RSV) and multiple myeloma, among others. The therapy has shown positive results in Phase III trials in both breast and lung cancer.

Drugs 174

Drugs Therapies Treatment Virus 174

Drug Target Review

SEPTEMBER 7, 2023

host disease risks. The first clinical candidate, BSB-1001, aims to transform leukemia treatment by targeting minor histocompatibility antigen-1. This two-part therapy aligns with allogeneic hematopoietic stem cell transplantation to enhance patient outcomes. leukaemia (GVL) effect while limiting graft-vs-host-disease.

Treatment 98

Treatment Licensing Licensing Disease 98

Drug Discovery World

MAY 3, 2024

Whether it is successful seed funding or dedicated investment, this money enables scientists to produce top-quality research which will in turn result in discoveries and drugs that help tackle disease and areas of unmet need. Cancer vaccine developer secures £12.8m Here are five financial success stories that made headlines this week.

Drugs 130

Drugs Vaccine Disease Treatment 130

Drug Discovery World

JANUARY 9, 2023

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines. . The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. .

Research 130

Research Vaccine Government Clinical Trials 130

Drug Discovery World

FEBRUARY 15, 2024

The etherna paradigm for cLNP design is ushering in the rapid generation of novel families of delivery systems for not only vaccination but also for in vivo tolerisation for a host of autoimmune diseases.” The post LNP formulations produce strong immune responses, data shows appeared first on Drug Discovery World (DDW).

Immune Response 130

Immune Response Vaccine RNA Pharmaceutical Companies 130

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose. Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

Drug Discovery World

OCTOBER 30, 2023

The news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Clinical Trials 130

Clinical Trials Vaccine Therapies Trials 130

Drug Target Review

MAY 22, 2024

How does Circio’s circVec technology aim to enhance the potency and reduce the cost of current gold-standard gene therapy? As a first step, Circio is working on designing and validating circVec-AAV vectors for the treatment of genetic diseases, and testing these head-to-head against the mRNA-AAV equivalent in vivo.

Therapies 57

Therapies RNA Protein Expression DNA 57

Drug Discovery World

SEPTEMBER 14, 2023

Total revenue from oncology medicines increased 22%, CVRM 20%, R&I8 10%, and rare disease 12%. Vaccines were up 9.1% Moreover, in July 2023, AstraZeneca and Vaxess Technologies commenced a collaboration for the evaluation of a novel RNA-based pandemic influenza prototype vaccine in patch format. Specialty care grew 11.8%

Vaccine 148

Vaccine FDA Approval Drugs Licensing 148

Drug Discovery World

MARCH 31, 2023

As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.

Vaccine 130

Vaccine Drugs Clinical Trials International 130

Drug Discovery World

JULY 10, 2023

If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World , it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. Some of these will no doubt see more success than others.

Pharmaceuticals 130

Pharmaceuticals Therapies Vaccine Clinical Trials 130

Drug Discovery World

JULY 22, 2022

Covid-19 vaccines remain effective six months after second dose . Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.? . New combination therapy shows promise against lung cancers? .

DNA 130

DNA Clinical Trials Vaccine Virus 130

Drug Discovery World

DECEMBER 8, 2023

The news highlights this week are mostly focused around neuroscience, with new guiding principles and a drug repurposing fund launched for motor neuron disease research, a new drug target found for early-onset dementia, and a possibly game-changing schizophrenia drug entering human trials.

DNA 130

DNA Drugs Clinical Trials Trials 130

Drug Discovery World

SEPTEMBER 15, 2023

First patient dosed in Phase Ib study in small cell lung cancer Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has dosed the first patient with its first-in-class lead molecule, satoreotide, targeting extensive stage small cell lung cancer (ES-SCLC).

Pharma Companies 130

Pharma Companies Drugs RNA Vaccine 130

Drug Discovery World

AUGUST 30, 2022

A new study has found that the antiviral tecovirimat (TPOXX) appears to be safe and effective for the treatment of monkeypox symptoms and skin lesions. TPOXX is an FDA-approved antiviral drug for the treatment of smallpox. Context and treatment. All patients completed the tecovirimat therapy and tolerated their treatment well.

Therapies 130

Therapies FDA Approval Vaccine Treatment 130

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Discovery World

FEBRUARY 10, 2023

The top stories: Study shines a light on representation in clinical research A diversity study has shown that clinical trials should use real world diseases epidemiology data, rather than US Census Bureau race and ethnicity data, to ensure enrolment reflects the populations affected by different diseases.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

Drug Discovery World

DECEMBER 16, 2022

The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia. . New dermatitis treatment shows promising long-term results . mRNA cancer vaccine meets primary efficacy endpoint .

Vaccine 130

Vaccine Drugs Clinical Trials Treatment 130

Drug Discovery World

JULY 20, 2023

The US Food and Drug Administration (FDA) has granted marketing authorisations to several new therapeutics over the last month that will have a significant impact on areas of unmet need and the evolution of future treatments.

FDA Approval 100

FDA Approval FDA Virus Therapies 100

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. at Month 7). Juan Carlos Jaramillo M.D., About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

Drug Discovery World

OCTOBER 31, 2022

The last month has seen huge strides forward in our understanding of cancers, particularly in how they develop resistance to therapies and how we can ‘outsmart’ them using gene editing or different therapeutic pathways, but also how we can better target drugs to individuals and accurately predict treatment outcomes.

Research 130

Research Vaccine Drugs DNA 130